Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9233227 | 0.92 | CRBN (0.54) | CYP2D6CRBNDDB1KMT2ASIGMAR1 | |
| SCHEMBL30069377 | 0.92 | CRBN (0.54) | CYP2D6CRBNDDB1KMT2ASIGMAR1 | |
| SCHEMBL22144489 | 0.86 | GAA (0.53) | CYP2D6CRBNDDB1KMT2ASIGMAR1 | |
| SCHEMBL5192402 | 0.83 | LTA4H (0.61) | CRBNDDB1KMT2ASIGMAR1CYP3A4 | |
| SCHEMBL26300907 | 0.77 | CRBN (0.40) | CRBNDDB1ALDH1A1 | |
| SCHEMBL18491021 | 0.76 | PDE7A (0.52) | CYP2D6KMT2ASIGMAR1CYP3A4TSHR | |
| SCHEMBL29080080 | 0.74 | CRBN (0.54) | CYP2D6CRBNDDB1KMT2ACYP3A4 | |
| SCHEMBL18132154 | 0.74 | CRBN (0.54) | CYP2D6CRBNDDB1KMT2ACYP3A4 | |
| SCHEMBL24536234 | 0.74 | CYP2D6 (0.53) | CYP2D6SIGMAR1CYP3A4TSHRALDH1A1 | |
| SCHEMBL17609064 | 0.73 | CYP2D6 (0.56) | CYP2D6SIGMAR1CYP3A4TSHRLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559915-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-4013755-B1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-114585622-B | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021028854-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | CYP2D6 4059/4885CRBN 2375/4885DDB1 248/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | CYP2D6 4059/4885CRBN 2375/4885DDB1 248/4885 |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | CYP2D6 2496/4885CRBN 4818/4885DDB1 948/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | CYP2D6 4059/4885CRBN 2375/4885DDB1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.